Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jianmin Pharmaceutical GroupLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Jianmin Pharmaceutical GroupLtd has a total shareholder equity of CN¥2.3B and total debt of CN¥94.4M, which brings its debt-to-equity ratio to 4.1%. Its total assets and total liabilities are CN¥4.1B and CN¥1.8B respectively. Jianmin Pharmaceutical GroupLtd's EBIT is CN¥231.7M making its interest coverage ratio -0.9. It has cash and short-term investments of CN¥749.2M.

Anahtar bilgiler

4.1%

Borç/özkaynak oranı

CN¥94.40m

Borç

Faiz karşılama oranı	-0.9x
Nakit	CN¥749.24m
Eşitlik	CN¥2.32b
Toplam yükümlülükler	CN¥1.75b
Toplam varlıklar	CN¥4.07b

Son finansal sağlık güncellemeleri

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30

Recent updates

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Sep 25

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

Aug 25

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

Jul 12

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 600976's short term assets (CN¥2.4B) exceed its short term liabilities (CN¥1.7B).

Uzun Vadeli Yükümlülükler: 600976's short term assets (CN¥2.4B) exceed its long term liabilities (CN¥79.2M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 600976 has more cash than its total debt.

Borcun Azaltılması: 600976's debt to equity ratio has increased from 0% to 4.1% over the past 5 years.

Borç Kapsamı: 600976's debt is well covered by operating cash flow (259.3%).

Faiz Kapsamı: 600976 earns more interest than it pays, so coverage of interest payments is not a concern.

Jianmin Pharmaceutical GroupLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Recent updates

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 24%

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥25.64

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin